HLB Co. Ltd Total Assets
HLB Co. Ltd total assets. Based on the latest financial reports, HLB Co. Ltd (028300) holds total assets worth ₩925.44 Billion KRW (≈ $627.16 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HLB Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of HLB Co. Ltd (2005–2025)
Total assets of HLB Co. Ltd from 2005 to 2025. This chart illustrates how HLB Co. Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of HLB Co. Ltd for real-time trading data and today's change.
HLB Co. Ltd - Asset Composition Analysis
HLB Co. Ltd Total Assets Breakdown (December 2025)
HLB Co. Ltd total assets breakdown as of December 2025. HLB Co. Ltd's total assets of ₩925.44 Billion consist of 13.4% current assets and 86.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.4% |
| Accounts Receivable | ₩9.52 Billion | 1.0% |
| Inventory | ₩9.45 Billion | 1.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩255.82 Billion | 27.5% |
| Goodwill | ₩77.83 Billion | 8.4% |
Asset Composition Trend (2005–2025)
This chart illustrates how HLB Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore HLB Co. Ltd (028300) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HLB Co. Ltd's current assets represent 13.4% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 4.4% of total assets in 2025, down from 17.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 27.5% of total assets.
HLB Co. Ltd Competitors by Total Assets
Key competitors of HLB Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
HLB Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.28 | 0.67 | 2.34 |
| Quick Ratio | 0.24 | 0.61 | 2.27 |
| Cash Ratio | 0.00 | 0.31 | 2.03 |
| Working Capital | ₩-252.75 Billion | ₩-65.80 Billion | ₩123.69 Billion |
HLB Co. Ltd - Advanced Valuation Insights
This section examines the relationship between HLB Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.48 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | ₩930.18 Billion |
| Market Capitalization | $3.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values HLB Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: HLB Co. Ltd's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HLB Co. Ltd (2005–2025)
The table below shows the annual total assets of HLB Co. Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩930.18 Billion ≈ $630.37 Million |
+4.82% |
| 2024-12-31 | ₩887.42 Billion ≈ $601.40 Million |
+18.05% |
| 2023-12-31 | ₩751.72 Billion ≈ $509.43 Million |
-22.28% |
| 2022-12-31 | ₩967.27 Billion ≈ $655.50 Million |
+30.06% |
| 2021-12-31 | ₩743.69 Billion ≈ $503.99 Million |
+5.27% |
| 2020-12-31 | ₩706.48 Billion ≈ $478.77 Million |
+94.83% |
| 2019-12-31 | ₩362.61 Billion ≈ $245.74 Million |
+19.26% |
| 2018-12-31 | ₩304.04 Billion ≈ $206.04 Million |
+61.56% |
| 2017-12-31 | ₩188.19 Billion ≈ $127.54 Million |
+0.80% |
| 2016-12-31 | ₩186.71 Billion ≈ $126.53 Million |
+0.83% |
| 2015-12-31 | ₩185.17 Billion ≈ $125.49 Million |
+241.32% |
| 2014-12-31 | ₩54.25 Billion ≈ $36.77 Million |
+50.27% |
| 2013-12-31 | ₩36.10 Billion ≈ $24.47 Million |
-5.60% |
| 2012-12-31 | ₩38.24 Billion ≈ $25.92 Million |
-29.51% |
| 2011-12-31 | ₩54.25 Billion ≈ $36.76 Million |
-6.64% |
| 2010-12-31 | ₩58.11 Billion ≈ $39.38 Million |
-28.68% |
| 2009-12-31 | ₩81.48 Billion ≈ $55.22 Million |
+16.90% |
| 2008-12-31 | ₩69.70 Billion ≈ $47.23 Million |
+45.04% |
| 2007-12-31 | ₩48.05 Billion ≈ $32.56 Million |
+48.89% |
| 2006-12-31 | ₩32.27 Billion ≈ $21.87 Million |
+30.35% |
| 2005-12-31 | ₩24.76 Billion ≈ $16.78 Million |
-- |
About HLB Co. Ltd
HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, inclu… Read more